Trials / Terminated
TerminatedNCT03472560
A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)
A PHASE 2, OPEN LABEL STUDY TO EVALUATE SAFETY AND CLINICAL ACTIVITY OF AVELUMAB (BAVENCIO (REGISTERED)) IN COMBINATION WITH AXITINIB (INLYTA (REGISTERED)) IN PATIENTS WITH ADVANCED OR METASTATIC PREVIOUSLY TREATED NON-SMALL CELL LUNG CANCER OR TREATMENT NAÏVE CISPLATIN-INELIGIBLE UROTHELIAL CANCER JAVELIN MEDLEY VEGF
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 61 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 2 study to evaluate the safety and efficacy of avelumab in combination with axitinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior platinum containing therapy, and in treatment naïve patients with advanced or metastatic urothelial cancer, who are ineligible for cisplatin containing chemotherapy for their advanced disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Avelumab (MSB0010718C) | IV treatment: Avelumab administered at 800 mg IV every two weeks |
| DRUG | Axitinib (AG-013736) | Oral treatment: Axitinib given 5 mg PO BID |
Timeline
- Start date
- 2018-05-02
- Primary completion
- 2023-02-09
- Completion
- 2023-02-09
- First posted
- 2018-03-21
- Last updated
- 2024-04-09
- Results posted
- 2024-04-09
Locations
39 sites across 8 countries: United States, Hungary, Italy, Poland, Russia, South Korea, Spain, Taiwan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03472560. Inclusion in this directory is not an endorsement.